Amoxicillin versus Cotrimoxazole for Treating Non-severe Pneumonia: A Systematic Review
Abstract
Introduction: Pneumonia is still one of the common causes of death in children under 5 years old in low-middle-income countries. The common cause of pneumonia is bacteria, requiring antibiotics as treatment. This systematic review evaluates the efficacy of amoxicillin and cotrimoxazole in treating pneumonia. Methods: This systematic review used PRISMA rules to analyze Pubmed and Europe PMC articles. The dose, duration, and therapeutic failure of amoxicillin and cotrimoxazole were assessed. Results: A total of 336 articles were selected for title and abstract screening. Four articles met the requirements, and two were selected for systematic review analysis. A total of 20,646 patients were analyzed, 11,633 (56.3%) received amoxicillin and 9,013 (43.7%) received cotrimoxazole. There was no significant difference in treatment failure between amoxicillin and cotrimoxazole. Conclusion: Amoxicillin has the same efficacy as cotrimoxazole for the management of non-severe pneumonia in children under 5 years old.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 20,646 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.